They found that their peptidomimetic, named D2, was able to specifically disrupt the binding of PELP1 to AR with an IC50 of 40 nM, preventing AR translocation, resulting in decreased growth of cancer cells in vitro, in vivo, and ex vivo (113). Here, PELP1 is linked to cancer.